Clinical Trial

A Phase I Clinical Trial of Single Subcutaneous Injection or Intravenous Infusion of SHR-1139 Injection in Healthy Chinese Subjects and Multiple Subcutaneous Injections in Patients With Moderate-to-severe Plaque Psoriasis

Completed Phase 1
View on ClinicalTrials.gov →
Summary
This is a clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic and immunogenicity of SHR-1139 injection in healthy subjects who receive a single subcutaneous injection or intravenous infusion of SHR-1139 injection, and in patients with moderate - to - severe plaque psoriasis who receive multiple subcutaneous injections of SHR-1139 injection.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-06-26; most recent amendment 2026-01-27.
Status change: Active, Not Recruiting → Completed 2026-01-27
Trial Details
NCT Number NCT07051538
Lead Sponsor Guangdong Hengrui Pharmaceutical Co., Ltd
Conditions Moderate to Severe Plaque Psoriasis
Enrollment 64 participants
Start Date 2024-06-26
Primary Completion 2025-11-28 (estimated)
Study Completion 2025-11-28 (estimated)
Updated on ClinicalTrials.gov 2026-01-28